北京大学JDB电子官方网站院长论坛

(Dean’s Forum of School of Basic Medical Sciences )

 

报告题目： Mouse models of diabetic nephropathy: will results translate to human disease? 

报 告 人： Matthew D. Breyer, M.D. 

                        Chief Scientific Officer （CSO） 

                        Lead Generation Biology 

                        Biotechnology Discovery Research 

                        Lilly Research Laboratories (礼来制药公司) 

时    间： 2010年6月2日 （星期三）上午10:30

地    点：医学部逸夫教学楼509

主 持 人：管又飞 教授

 

讲座人简历：

1979-1982：       Internal Medical Residency

1982-1985：       Nephrology Postdoctoral Fellowship，University of Texas Health Science Center, Dallas, TX

1985-1992：       Assistant Professor，Vanderbilt University，Department of Medicine,

1992- 2000：      Associate Professor，Vanderbilt University，Department of Medicine, Division of Nephrology

1993-2000：       Associate Professor，Vanderbilt University，Department of Molecular Physiology and Biophysics

2000-2002：       Professor，Vanderbilt University Department of Medicine and Molecular Physiology and Biophysics

2002-2007：       Catherine McLaughlin Hakim Professor of Medicine，Vanderbilt University Department of Medicine

2007-2009：   Sr Medical Fellow II，Biotherapeutics Discovery Research，Eli Lilly and Company，Indianapolis IN

 

2009-present： Chief Scientific Officer，Lead Generation Biology，Biotherapeutics Discovery Research，Eli Lilly and Company，Indianapolis IN

 

Job responsibilities: To direct the biology of the discovery, pre-lead to first human dose portfolio in Biotherapeutics at Eli Lilly.  This team is comprised of fifty Lilly biologists exploring indications for novel biological in the treatment of disease indications including  diabetes, cardiovascular disease, metabolic bone disease, cancer, neurologic disease, autoimmune inflammatory disease, and kidney disease.